ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ АГОНИСТОВ АДЕНОЗИНОВЫХ И ОПИОИДНЫХ РЕЦЕПТОРОВ ДЛЯ ПРЕДУПРЕЖДЕНИЯ РЕПЕРФУЗИОННЫХ ПОВРЕЖДЕНИЙ СЕРДЦА. АНАЛИЗ ЭКСПЕРИМЕНТАЛЬНЫХ И КЛИНИЧЕСКИХ ДАННЫХ

Обложка


Цитировать

Полный текст

Аннотация

В Российской Федерации внутригоспитальная летальность после острого инфаркта миокарда составляет 16,5–16,7%. Часть пациентов погибают уже после реканализации инфарктсвязанной коронарной артерии в результате реперфузионных повреждений сердца. Экспериментальные данные свидетельствуют, что агонисты аденозиновых рецепторов и опиоиды могут предупреждать реперфузионные повреждения сердца, т.е. имитировать феномен посткондиционирования. Данные клинических наблюдений показывают, что аденозин при внутривенной инфузии, интракоронарном введении при тромболизисе или чрескожном коронарном вмешательстве оказывает инфарктлимитирующий эффект и устраняет проявления феномена «no-reflow». Клинические данные свидетельствуют, что морфин способен предупреждать реперфузионные повреждения сердца у человека. Таким образом, анализ литературных данных говорит о том, что агонисты аденозиновых и опиоидных рецепторов могут стать прототипом для разработки препаратов для профилактики реперфузионных повреждений сердца.

 

Об авторах

Д. Н. Маслов

НИИ кардиологии, Томск

Автор, ответственный за переписку.
Email: Maslov@cardio-tomsk.ru
доктор медицинских наук, профессор, руководитель лаборатории экспериментальной кардиологии НИИ кардиологии Россия

А. Г. Мрочек

Республиканский научно-практический центр «Кардиология», Минск

Email: a.mrochek@mail.by
доктор медицинских наук, профессор, академик Национальной академии наук Беларуси, директор Республиканского научно-практического центра «Кардиология» Белоруссия

И. Г. Халиулин

Университет Бристоля

Email: I.Khaliulin@bristol.ac.uk
кандидат медицинских наук, научный сотрудник лаборатории биохимии Университета Бристоля Великобритания

А. В. Крылатов

Институт физиологии им. А.А. Богомольца, Киев

Email: port@serv.biph.kiev.ua
кандидат медицинских наук, старший научный сотрудник отдела общей и молекулярной патофизиологии Института физиологии им. А.А. Богомольца Украина

А. Г. Портниченко

Еврейский университет Иерусалима

Email: evchik@inbox.ru
кандидат медицинских наук, научный сотрудник отдела биологии развития и исследования рака факультета медицины Еврейского университета Иерусалима Израиль

Е. Чаусская

НИИ кардиологии, Томск, Российская Федерация

Email: Maslov@cardio-tomsk.ru

MD, senior research scientist of the Laboratory of Experimental Cardiology of Research Institute of Cardiology. Address: 111, Kievskaya Street, Tomsk, RF, 634012, tel.: +7 (3822) 26-21-74

Россия

Н. В. Нарыжная

НИИ кардиологии, Томск, Российская Федерация

Email: natalynar@yandex.ru
kandidat meditsinskikh nauk, starshii nauchnyi sotrudnik laboratorii ekspe-rimental’noi kardiologii NII kardiologii
Address: 111, Kievskaya Street, Tomsk, RF, 634012, tel.: +7 (3822) 26-21-74 Россия

А. С. Горбунов

НИИ кардиологии, Томск, Российская Федерация

Email: barabator@sibmail.com

kandidat meditsinskikh nauk, mladshii nauchnyi sotrudnik laboratorii eksperimental’noi kardiologii NII kardiologii
Address: 111, Kievskaya Street, Tomsk, RF, 634012, tel.: +7 (3822) 26-21-74

Россия

С. Ю. Цибульников

НИИ кардиологии, Томск, Российская Федерация

Email: seregka2010@hotmail.com
kandidat meditsinskikh nauk, mladshii nauchnyi sotrudnik laboratorii eksperimental’noi kardiologii NII kardiologii
Address: 111, Kievskaya Street, Tomsk, RF, 634012, tel.: +7 (3822) 26-21-74 Россия

Список литературы

  1. Nikolaeva N.V., Fedorov V.V., Privalova V.Yu., Gal'yanov A.A. Kardiologiya = Cardiology. 1997; 37(3): 73.
  2. Shal'nova S.A., Deev A.D. Ter. arkhiv = Therapeutic archive. 2011; 83(1): 7–12.
  3. Oganov R.G., Pogosova G.V. Kardiologiya = Cardiology. 2007; 47(12): 4–9.
  4. Chazov E.I. Ter. arkhiv = Therapeutic archive. 2008; 80(8): 11–16.
  5. Gafarov V.V., Gafarova A.V. Ter. arkhiv = Therapeutic archive. 2011; 83(1): 38–45.
  6. Oganov R.G., Maslennikova G.Ya. Kardiologiya = Cardiology. 2007; 47(1): 4–7.
  7. Gafarov V.V. Ter. arkhiv = Therapeutic archive. 2000; 72 (1): 15–21.
  8. Sidorenkov O., Nilssen O., Nieboer E., Kleshchinov N., Grjibovski A.M. Premature cardiovascular mortality and alcohol consumption before death in Arkhangelsk, Russia: an analysis of a consecutive series of forensic autopsies. Int. J. Epidemiol. 2011; 40 (6): 1519–1529.
  9. Yavelov I.S., Gratsianskii N.A. Kardiologiya = Cardiology. 2004; 44(4): 4–13.
  10. Simes R.J., O’Connell R.L., Aylward P.E., Varshavsky S., Diaz R., Wilcox R.G., Armstrong P.W., Granger C.B., French J.K., Van de Werf F., Marschner I.C., Califf R., White H.D.; HERO-2 Investigators. Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Am. Heart J. 2010; 159 (6): 988–997.
  11. Erlikh A.D., Gratsianskii N.A. Kardiologiya = Cardiology. 2009; 49(7–8): 4–12.
  12. Maslov L.N. Angiol. sosud. khirurgiya = Angiology and vascular surgery. 2007; 13(4): 9–19.
  13. Gafarov V.V., Blaginina M.Yu. Kardiologiya = Cardiology. 2005; 45(8): 48–50.
  14. Gafarov V.V., Gafarova A.V., Blaginina M.Yu. Kardiologiya = Cardiology. 2005; 45(8): 48–50.
  15. Antman E.M., Morrow D.A., McCabe C.H., Murphy S.A., Ruda M., Sadowski Z., Budaj A., Lоpez-Sendоn J.L., Guneri S., Jiang F., White H.D., Fox K.A., Braunwald E.; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 2006; 354 (14): 1477–1488.
  16. Panova E.I. Klin. med = Clinical medicine. 2008; 86(12): 19–23.
  17. Syrkin A.S. Infarkt miokarda [Myocardial Infarction]. Moscow, MIA, 2003. 466 p.
  18. Curtis M.J., Macleod B.A., Walker M.J.A. Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat. J. Mol. Cell. Cardiol. 1987; 19 (4): 399–419.
  19. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74 (5): 1124–1136.
  20. Alker K.J., Bellows S.D., Kloner R.A. Stuttering reperfusion of ischemic myocardium does not exacerbate myocardial infarction: evidence against lethal cell reperfusion injury in the rabbit. J. Thromb. Thrombolysis. 1996; 3 (3): 185–188.
  21. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2003; 285 (2): 579–588.
  22. Jordan J.E., Zhao Z.Q., Sato H., Taft S., Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J. Pharmacol. Exp. Ther. 1997; 280 (1): 301–309.
  23. Philipp S., Yang X.M., Cui L., Davis A.M., Downey J.M., Cohen M.V. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc. Res. 2006; 70 (2): 308–314.
  24. Yang Z., Day Y.J., Toufektsian M.C., Ramos S.I., Marshall M., Wang X.Q., French B.A., Linden J. Infarct-sparing effect of A2Aadenosine receptor activation is due primarily to its action on lymphocytes. Circulation. 2005; 111 (17): 2190–2197.
  25. Yang Z., Day Y.J., Toufektsian M.C., Xu Y., Ramos S.I., Marshall M.A., French B.A., Linden J. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation. 2006; 114 (19): 2056–2064.
  26. Garratt K.N., Holmes D.R., Molina-Viamonte V., Reeder G.S., Hodge D.O., Bailey K.R., Lobl J.K., Laudon D.A., Gibbons R.J. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am. Heart J. 1998; 136 (2): 196–204.
  27. Cohen M.V., Downey J.M. Adenosine: trigger and mediator of cardioprotection. Basic Res. Cardiol. 2008; 103 (3): 203–215.
  28. Klabunde R.E. Dipyridamole inhibition of adenosine metabolism in human blood. Eur. J. Pharmacol. 1983; 93(1–2): 21–26.
  29. Mahaffey K.W., Puma J.A., Barbagelata N.A., DiCarli M.F., Leesar M.A., Browne K.F., Eisenberg P.R., Bolli R., Casas A.C., Molina-Viamonte V., Orlandi C., Blevins R., Gibbons R.J., Califf R.M., Granger C.B. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial. J. Am. Coll. Cardiol. 1999; 34 (6): 1711–1720.
  30. Ross A.M., Gibbons R.J., Stone G.W., Kloner R.A., Alexander R.W. AMISTAD-II Investigators. A randomized, double-blinded, placebocontrolled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol. 2005; 45 (11): 1775–1780.
  31. Micari A., Belcik T.A., Balcells E.A., Powers E., Wei K., Kaul S., Lindner J.R. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am. J. Cardiol. 2005; 96 (10): 1410–1415.
  32. Kloner R.A., Forman M.B., Gibbons R.J., Ross A.M., Alexander R.W., Stone G.W. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur. Heart J. 2006; 27 (20): 2400–2405.
  33. Sakuma T., Motoda C., Tokuyama T., Oka T., Tamekiyo H., Okada T., Otsuka M., Okimoto T., Toyofuku M., Hirao H., Muraoka Y., Ueda H., Masaoka Y., Hayashi Y. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular function in patients with acute anterior myocardial infarction: a study using myocardial contrast echocardiography. Int. J. Cardiol. 2010; 140 (2): 200–209.
  34. North R.A. Molecular physiology of P2X receptors. Physiol. Rev. 2002; 82 (4): 1013–1067.
  35. Wang J., Chen Y.D., Zhi G., Xu Y., Chen L., Liu H.B., Zhou X., Tian F. Beneficial effect of adenosine on myocardial perfusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction. Clin. Exp. Pharmacol. Physiol. 2012; 39 (3): 247–252.
  36. Marzilli M., Orsini E., Marraccini P., Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000; 101 (18): 2154–2159.
  37. Claeys M.J., Bosmans J., De Ceuninck M., Beunis A., Vergauwen W., Vorlat A., Vrints C.J. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am. J. Cardiol. 2004; 94 (1): 9–13.
  38. Vijayalakshmi K., Whittaker V.J., Kunadian B., Graham J., Wright R.A., Hall J.A., Sutton A., de Belder M.A. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006; 92 (9): 1278–1284.
  39. Parikh K.H., Chag M.C., Shah K.J. Shah U.G., Baxi H.A.,
  40. Chandarana A.H., Naik A.M., Shah J.N., Shah H.D., Goyal R.K. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can. J. Physiol. Pharmacol. 2007; 85 (3–4): 476–482.
  41. Stoel M.G., Marques K.M., de Cock C.C., Bronzwaer J.G., von Birgelen C., Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebocontrolled pilot study. Catheter Cardiovasc. Interv. 2008; 71 (3): 283–289.
  42. Tian F., Chen Y.D., Lu S.Z., Song X.T., Yuan F., Fang F., Li Z.A. Intracoronary adenosine improves myocardial perfusion in late reperfused myocardial infarction. Chin. Med. J. 2008; 121 (3): 195–199.
  43. Grygier M., Araszkiewicz A., Lesiak M., Janus M., Kowal J., Skorupski W., Pyda M., Mitkowski P., Grajek S. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am. J. Cardiol. 2011; 107 (8): 1131–1135.
  44. Niccoli G., Rigattieri S., De Vita M.R., Valgimigli M., Corvo P., Fabbiocchi F., Romagnoli E., De Caterina A.R., La Torre G., Lo Schiavo P., Tarantino F., Ferrari R., Tomai F., Olivares P., Cosentino N., D’Amario D., Leone A.M., Porto I., Burzotta F., Trani C., Crea F. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013; 6 (6): 580–589.
  45. Quintana M., Hjemdahl P., Sollevi A., Valgimigli M., Corvo P., Fabbiocchi F., Romagnoli E., De Caterina A.R., La Torre G., Lo Schiavo P., Tarantino F., Ferrari R., Tomai F., Olivares P., Cosentino N., D’Amario D., Leone A.M., Porto I., Burzotta F., Trani C., Crea F. ATTACC investigators. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur. J. Clin. Pharmacol. 2003; 59 (1): 1–9.
  46. Fokkema M.L., Vlaar P.J., Vogelzang M., Gu Y.L., Kampinga M.A., de Smet B.J., Jessurun G.A., Anthonio R.L., van den Heuvel A.F., Tan E.S., Zijlstra F. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ. Cardiovasc. Interv. 2009; 2 (4): 323–329.
  47. Peart J.N., Gross E.R., Reichelt M.E., Hsu A., Headrick J.P., Gross G.J. Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts. Basic Res. Cardiol. 2008; 103 (5): 454–463.
  48. Bolli R., Triana J.F., Jeroudi M.O. Prolonged impairment of coronary vasodilation after reversible ischemia. Evidence for microvascular «stunning». Circ. Res. 1990; 67 (2): 332–343.
  49. Desmet W., Bogaert J., Dubois C., Sinnaeve P., Adriaenssens T., Pappas C., Ganame J., Dymarkowski S., Janssens S., Belmans A., Van de Werf F. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur. Heart J. 2011; 32 (7): 867–877.
  50. Kopecky S.L., Aviles R.J., Bell M.R., Lobl J.K., Tipping D., Frommell G., Ramsey K., Holland A.E., Midei M., Jain A.,
  51. Kellett M., Gibbons R.J. AmP579 Delivery for Myocardial Infarction REduction study. A randomized, double-blinded, placebocontrolled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am. Heart J. 2003; 146 (1): 146–152.
  52. Smits G.J., McVey M., Cox B.F., Lobl J.K., Tipping D., Frommell G., Ramsey K., Holland A.E., Midei M., Jain A., Kellett M., Gibbons R.J. Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J. Pharmacol. Exp. Ther. 1998; 286 (2): 611–618.
  53. Gross E.R., Hsu A.K., Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ. Res. 2004; 94 (7): 960–966.
  54. Chang W.L., Lee S.S., Su M.J. Attenuation of post-ischemia reperfusion injury by thaliporphine and morphine in rat hearts. J. Biomed. Sci. 2005; 12 (4): 611–619.
  55. Gross E.R., Hsu A.K., Gross G.J. Diabetes abolishes morphineinduced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3b. Diabetes. 2007; 56 (1): 127–136.
  56. Gross E.R., Hsu A.K., Gross G.J. GSK3b inhibition and KATP channel opening mediate acute opioid-induced cardioprotection at reperfusion. Basic Res. Cardiol. 2007; 102 (4): 341–349.
  57. Tsutsumi Y.M., Yokoyama T., Horikawa Y., Roth D.M., Patel H.H. Reactive oxygen species trigger ischemic and pharmacological postconditioning: in vivo and in vitro characterization. Life Sci. 2007; 81 (15): 1223–1227.
  58. Forster K., Kuno A., Solenkova N., Felix S.B., Krieg T. The d-opioid receptor agonist DADLE at reperfusion protects the heart through activation of pro-survival kinases via EGF receptor transactivation. Am. J. Physiol. Heart Circ. Physiol. 2007; 293 (3): 1604–1608.
  59. Chen Z., Li T., Zhang B. Morphine postconditioning protects against reperfusion injury in the isolated rat hearts. J. Surg. Res. 2008; 145 (2): 287–294.
  60. Jang Y., Xi J., Wang H., Mueller R.A., Norfleet E.A., Xu Z. Postconditioning prevents reperfusion injury by activating δ-opioid receptors. Anesthesiology. 2008; 108 (2): 243–250.
  61. Kim J.H., Chun K.J., Park Y.H., Kim J., Kim J.S., Jang Y.H., Lee M.Y., Park J.H. Morphine-induced postconditioning modulates mitochondrial permeability transition pore opening via delta-1 opioid receptors activation in isolated rat hearts. Korean J. Anesthesiol. 2011; 61 (1): 69–74.
  62. Gong Z.X., Ran K., Chang Y.T., Xu J.M. Effect of morphine postconditioning on myocardial ischemia-reperfusion injury in rabbits. J. Zhejiang Univ. Med. Sci. 2009; 38 (5): 521–524.
  63. Mourouzis I., Saranteas T., Perimenis P., Tesseromatis C., Kostopanagiotou G., Pantos C., Cokkinos D.V. Morphine
  64. administration at reperfusion fails to improve postischaemic cardiac function but limits myocardial injury probably via heat-shock protein 27 phosphorylation. Eur. J. Anaesthesiol. 2009; 26 (7): 572–581.
  65. Huhn R., Heinen A., Weber N.C., Schlack W., Preckel B., Hollmann M.W. Ischaemic and morphine-induced post-conditioning: impact of mKCa channels. Brit. J. Anaesth. 2010; 105 (5): 589–595.
  66. Fuardo M., Lemoine S., Lo Coco C., Hanouz J.L., Massetti M. [D-Ala2,D-Leu5]-enkephalin (DADLE) and morphine-induced postconditioning by inhibition of mitochondrial permeability transition pore, in human myocardium. Exp. Biol. Med. (Maywood). 2013; 238 (4): 426–432.
  67. Zhang R., Shen L., Xie Y., Gen L., Li X., Ji Q. Effect of morphineinduced postconditioning in corrections of tetralogy of Fallot. J. Cardiothorac. Surg. 2013; 8: 76.
  68. Metelitsa V.I. Spravochnik po klinicheskoi farmakologii serdechno-sosudistykh lekarstvennykh sredstv [Guide in Clinical Pharmacology of Cardiovascular Medicines]. Moscow, BINOM; St. Petersburg, Nevskii Dialekt, 2002. 926 p.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Издательство "Педиатръ", 1970



Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах